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Objectives: Despite several publications on the analytical performance of high-sensitivity cardiac
troponin (hs-cTn) assays, there has been little information on how laboratories should validate and
implement these assays into clinical service. Our study provides a practical approach for the validation
and implementation of a hs-cTn assay across a large North American City.
Design and methods: Validation for the Abbott ARCHITECT hs-cTnI assay (across 5 analyzers) consisted of
veriﬁcation of limit of blank (LoB), precision (i.e., coefﬁcient of variation; CV) testing at the reported limit of
detection (LoD) and within and outside the 99th percentile, linearity testing, cTnI versus hs-cTnI patient
comparison within and between analyzers (Passing and Bablok and non-parametric analyses). Education,
clinical communications, and memorandums were issued in advance to inform all staff across the city as well
as a selected reminder the day before live-date to important users. All hospitals switched to the hs-cTnI assay
concurrently (the contemporary cTnI assay removed) with laboratory staff instructed to repeat samples
previously measured with the contemporary cTnI assay with the hs-cTnI assay only by physician request.
Results: Across the 5 analyzers and 6 reagent packs the overall LoB was 0.6 ng/L (n¼60) with a CV of 33% at an
overall mean of 1.2 ng/L (n¼60; reported LoD¼1.0 ng/L), with linearity demonstrated from 45,005 ng/L to
1.1 ng/L. Precision testing with a normal patient-pool QC material (mean range across 5 analyzers was 3.9–
4.4 ng/L) yielded a range of CVs from 7% to 10% (within-run) and CVs from 7% to 18% (between-run) with the
high patient-pool QC material (mean range across 5 analyzers was 29.6–36.3 ng/L) yielding a range of CVs from
2% to 5% (within-run) and CVs from 4% to 8% (between-run). There was agreement between hs-cTnI versus
cTnI with the patient samples (slope ranges: 0.89–1.03; intercept ranges: 1.9–3.8 ng/L), however, the median
CV on patient samples o100 ng/L across the analyzers was 5.6% for hs-cTnI versus 18.7% for the contemporary
assay (po0.001). Following the switch to hs-cTnI testing, no requests for repeat measurements were received.
Conclusions: Validation and implementation of hs-cTnI testing across multiple sites requires collaboration
within the laboratories and between hospital laboratories and clinical staff.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The introduction of high-sensitivity cardiac troponin (hs-cTn) assays into clinical use has had varied success within Canada [1–3]. This
partly may be explained by insufﬁcient analytical, clinical and educational material widely available to efﬁciently and effectively institute
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/plabm
Practical Laboratory Medicine
http://dx.doi.org/10.1016/j.plabm.2015.02.001
2352-5517/& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
☆Funding: Abbott Diagnostics Canada provided calibrators and reagents for the validation.
☆☆Disclosures: PK has received grants/honorariums/consultant/advisor fees from Abbott Laboratories, Abbott Point of Care, Beckman Coulter, Ortho Clinical Diagnostics,
Roche Diagnostics, and the Canadian Agency for Drugs and Technologies in Health. He is listed as an inventor on patents ﬁled by McMaster University related to laboratory
testing in acute cardiac care.
n Correspondence to: Juravinski Hospital and Cancer Centre, 711 Concession Street Hamilton, ON, Canada L8V 1C3. Tel.: þ1 905 521 2100.
E-mail address: kavsakp@mcmaster.ca (P.A. Kavsak).
Practical Laboratory Medicine 1 (2015) 28–34
such a change within a North American city. There are, however, national and international materials published on the analytical aspects
[4–6], and there has been excellent evaluation studies, both single center [7,8] and multicenter studies [9,10] on the two clinically
approved hs-cTn assays in Canada (Roche Diagnostics hs-cTnT and Abbott Diagnostics hs-cTnI).
So why has there been problems, considering the reported analytical and clinical performance of the hs-cTn assays has always been
demonstrated to be superior to the contemporary assays [11–14]? One contributing factor could be the lack of consensus on the most
appropriate cutoff and interpretation for hs-cTn concentrations [3]. Another, more practical aspect for clinical laboratories, could be the
lack of published data on the key elements required for internal validation and implementation of hs-cTn assays. Locally, within the city of
Hamilton (population4500,000) after clinical consultation, consensus and support, all four acute-care hospital core laboratories
proceeded to implement hs-cTn testing. Detailed below is the step-by-step procedure followed by all laboratories for the validation
and implantation of a hs-cTnI assay with materials and supplies readily available in all the laboratories.
2. Material and methods
2.1. Hospital laboratories, quality control, reagents
The four hospital core laboratories were the Juravinski Hospital and Cancer Centre (JHCC; Abbott ARCHITECT i2000SR analyzer), the
Hamilton General Hospital (HGH; two Abbott ARCHITECT i2000SR analyzers), St. Joseph's Hospital (SJH; Abbott ARCHITECT i2000SR
analyzer) and McMaster Children's Hospital (MCH; Abbott ARCHITECT i1000 analyzer). The laboratory practice for all four core hospital
laboratories has been to prepare patient-pool quality control (QC) material (e.g., citrate phosphate dextrose plasma pool from Canadian
Blood Services spiked with cTn) [15,16] to monitor cTn at the 99th percentile. In preparation for transitioning to a hs-cTn assay, a “normal”
low patient-pool QC material was also prepared. Two different size hs-cTnI reagent packs (100-test and 500-test) were evaluated on the
JHCC analyzer as this analyzer was the ﬁrst to identify the ﬁrst replication outlier effect present with the 500-test pack size for the
contemporary Abbott cTnI assay on certain analyzers [17]. MCH was the only other site which evaluated the hs-cTnI 100-test pack (i1000
only supports 100-test packs), with HGH and SJH laboratories both evaluating the 500-test packs.
2.2. Limit of the blank and precision testing
Each site was instructed to run water as a patient 10 times on each instrument and reagent pack size (n¼60 in total, as 10 water tested
on 500-test pack and 100-test pack at JHCC). The limit of the blank (LoB) was determined by the mean concentration of the water
(n¼60)þ3SD. Patient-pool EDTA plasma with a measured concentration of approximately 1 ng/L (to reﬂect the reported limit of the
detection (LoD) for this assay) [8] at the JHCC was aliquoted, frozen (20 C) and distributed for testing on each analyzer and reagent pack
size (n¼60 in total measurements; performed as within-run). The normal patient-pool QC and high patient-pool QC material (frozen
aliquots below 70 C) were measured for within-run (n¼10 tests) and for between-run precision (over 4 weeks) on the 5 different
analyzers.
2.3. Linearity and patient comparison testing
An extremely high cTnI concentration EDTA patient-pool (approximately 50,000 ng/L, frozen below 20 C) was distributed to each site
for linearity testing. Each site performed 16 serial dilutions with the Abbott Diagnostic multi-assay diluent (manufacturer recommended
diluent for the hs-cTnI assay). Each site performed duplicate testing on each serial dilution (exception JHCC with the 100-pack). Linearity
was achieved if the site's measured concentrations at all 17 levels were within 2SD of the average measurement for each level. Forty frozen
(below 20 C) EDTA patient-pools (n¼8: o10 ng/L, n¼10: 10–30 ng/L, n¼13: 31–300 ng/L; n¼9: 4300 ng/L) were distributed to each
site to run for hs-cTnI and cTnI. The JHCC measured the 40 samples on the hs-cTnI 500-test pack, 100-test pack and the cTnI 100-test pack;
SJH measured the 40 samples on the hs-cTnI 500-test pack and the cTnI 100-test pack; MCH measured the 40 samples on the hs-cTnI
100-test pack and the cTnI 100-test pack; and the HGH measured the 40 samples on analyzer 1 in duplicate: hs-cTnI 500-test pack and
cTnI 500-test pack and on analyzer 2 in duplicate for the hs-cTnI 500-test pack. Passing and Bablok regression analyses were performed
with Analyse-it software with proportional or absolute differences noted only if the 95%CI of the slope or intercept did not include 1.00 or
0 ng/L, respectively. The average concentration of each sample across all analyzers for both hs-cTnI and cTnI were calculated as well as the
CV, with differences between hs-cTnI and cTnI measurements and imprecision assessed by Mann–Whiney non-parametric testing
(Statsdirect software, with two-sided po0.050 considered signiﬁcant).
2.4. Implementation of hs-cTnI
After clinical agreement and support for the hospitals’ core laboratories to proceed to switch cTnI testing to hs-cTnI testing, extensive
education and dissemination of this forthcoming change occurred via various educational activities and documents (targeted to all
hospital staff, trainees, and students). The day before the switch a targeted communication to the emergency departments, internal
medicine and cardiology services at the hospitals also occurred as a reminder. Each laboratory concurrently stop the contemporary cTnI
testing (reported in mg/L to two decimal places) and proceeded with hs-cTnI testing (reported in ng/L, and in whole numbers). The practice
of reporting hs-cTnI in whole numbers has been previously advocated and supported [6,18] and the following comment “nUnits (ng/L) as
high-sensitivity assay” was appended to the hs-cTnI results for further clarity.
As the stability of cTnI as measured by the Abbott hs-cTnI assay has already been documented [19], the core laboratory staff at all
hospitals were instructed after the switch to hs-cTnI testing to repeat samples previously measured with the contemporary cTnI assay
with the hs-cTnI assay only by physician request. To assess the impact on repeat testing; queries in the laboratory information system
databases were performed to identify if a previous specimen number with a cTnI result also had a hs-cTnI result. Finally, to assess overall
how the implementation proceeded, the Biochemist (PK) the following day asked each laboratory as well as directly following up with the
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targeted services (emergency medicine, internal medicine, and cardiology) if there were any concerns or problems with the
implementation.
3. Results
The Abbott hs-cTnI assay across 5 instruments and 6 reagent packs yielded a LoB of 0.6 ng/L. The average concentration in water was
0.12 ng/L with a CV¼141% (n¼60 measurements). The LoD has been reported as 1.0 ng/L [8], and a patient-pool targeted at this
concentration yielded an overall CV of 33% at an average concentration of 1.2 ng/L [n¼60]. The within-run precision of the normal patient-
pool QC material (n¼10) was as follows: SJH mean¼4.1 ng/L, CV¼10%; HGH-1 mean¼4.3 ng/L, CV¼10%; HGH-2 mean¼4.3 ng/L, CV¼7%,
JHCC mean¼4.1 ng/L, CV¼10%; MCH mean¼4.2, CV¼7%; with the high patient-pool QC material yielding the following within-run
precision: SJH mean¼33.7 ng/L, CV¼5%; HGH-1 mean¼29.6 ng/L, CV¼3%; HGH-2 mean¼34.9 ng/L, CV¼2%; JHCC mean¼32.7 ng/L,
CV¼4%; MCH mean¼34.7, CV¼3%. The between day performance over 4 weeks for each of these materials across the sites were as
follows: normal patient-pool QC mean range: 3.9–4.4 ng/L; CV range: 7–18%; high patient-pool QC mean range: 32.2–36.3 ng/L; CV range:
4–8% (n420 data points for each material on each analyzer).
Each of the analyzers demonstrated acceptable linearity with the average measurement for each of the 17 levels falling within the
allowable limits (72SD from the overall level average). Table 1 displays the overall average concentrations for the 17 different levels and
the upper and lower limits as well as the precision obtained from the 11 measurements per level. The last dilution was set to yield a result
below the LoD, and the absolute % difference between the overall average concentration and the predicted concentration was 1.2% on this
last dilution. Overall, there was r30% absolute difference between the average concentration and the predicted concentration.
The linearity regression analyses for the serial dilutions are illustrated in Fig. 1.
There was no signiﬁcant proportional difference (i.e., slope 95%CI included 1.00) between hs-cTnI versus cTnI by Passing and Bablok
regression analyses on the 5 analyzers assessing the different reagent combinations with the 40 patient-pool EDTA plasma samples;
however, there appeared to be a slight absolute bias (y-intercept). To address this, the average hs-cTnI concentrations (n¼8 measurements
for the 40 samples) was compared to the average cTnI concentrations (n¼5 measurements for the 40 samples). Passing and Bablok
regression analyses did indicate a small absolute bias (3.4 ng/L; 95%CI: 1.2–4.6) but no signiﬁcant proportional bias (see Fig. 2). Overall,
however, there was no signiﬁcant difference between the average concentrations measured with the hs-cTnI assay versus the
contemporary cTnI assay on these 40 samples (hs-cTnI median (25th–75th)¼41 ng/L (13–263) versus cTnI median (25th–75th)¼38 ng/L
(8–366), p¼0.59).
A comparison between the CVs of the two assays on these 40 patient-pool EDTA plasma samples, did indicate superior precision for the
hs-cTnI assay (hs-cTnI median CV¼5.6% versus cTnI median CV¼10.5%, p¼048). A closer examination indicated that samples (n¼15) with
concentrations 4100 ng/L there was no statistical difference between the CVs (hs-cTnI median CV¼5.7% versus cTnI median CV¼3.4%;
p¼0.074). However, below 100 ng/L (n¼25 samples) the hs-cTnI assay had superior precision (hs-cTnI median¼5.6% versus cTnI
median¼18.7%; po0.001) (see Fig. 3). Despite the excellent analytical precision of the hs-cTnI assay on the 40 patient-pool EDTA plasma
samples, there were still samples that gave different results on the different analyzers (see Table 2).
On the day of the implementation for the hs-cTnI assay, there were no physician requests to measure hs-cTnI on previous samples
reported with the contemporary cTnI assay. Laboratory and clinical staff within the hospitals reported no major issues.
4. Discussion
The hs-cTnI assay has superior precision at lower concentrations as compared to the contemporary cTnI assay and is more analytically
sensitivity (hs-cTnI LoD is 1 ng/L versus 10 ng/L or 0.01 mg/L for the contemporary cTnI assay). This study, which used available resources
and supplies, with a set protocol veriﬁed the LoB and the precision estimates previously reported for the Abbott ARCHITECT's hs-cTnI
assay [8]. The Clinical and Laboratory Standards Institute has very detailed and prescribed methods to determine the LoB and LoD;
however, the necessity to re-establish these estimates when literature provides these parameters may need to be re-evaluated. Another
Table 1
Linearity, precision and acceptable limits for 5 analyzers and the 500- and 100-test packs for hs-cTnI (ng/L).
Serial dilution Overall hs-cTnI assignment average (ng/L)
(All measurements, n¼11)
Standard deviation (SD) Coefﬁcient variation (CV) (%) Low (mean2SD) High (meanþ2SD)
Concentrate 45,004.6 1733.7 4 41,537.1 48,472.0
1 in 2 24,897.4 992.1 4 22,913.3 26,881.5
1 in 4 11,809.4 554.2 5 10,701.0 12,917.7
1 in 8 5355.1 263.9 5 4827.2 5883.0
1 in 16 2445.7 138.3 6 2169.0 2722.3
1 in 32 1153.3 89.8 8 973.8 1332.8
1 in 64 565.8 34.8 6 496.1 635.5
1 in 128 268.8 23.8 9 221.2 316.3
1 in 256 135.7 15.4 11 105.0 166.5
1 in 512 67.1 5.9 9 55.3 78.9
1 in 1024 33.2 4.3 13 24.6 41.8
1 in 2048 16.2 2.4 15 11.5 21.0
1 in 4096 8.0 1.1 14 5.8 10.2
1 in 8192 3.8 0.6 15 2.7 4.9
1 in 16,384 2.1 0.5 27 1.0 3.2
1 in 32,768 1.1 0.3 31 0.4 1.7
1 in 65,536 0.7 0.4 57 0.1 1.5
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Abbott ARCHITECT hs-cTnI linearity
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Fig. 1. Linear regression analysis for the serial dilutions for the hs-cTnI assay.
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mechanism that could be proposed for laboratories that may not have the resources or expertise to perform such extensive testing may be
of great value. Our study proposes such an alternative mechanism to verify the LoB, to test precision at the reported LoD, and assess the
linearity range. Evaluating all three variables across 5 different analyzers and 6 reagents packs, we have established the lower limit of
reporting for the hs-cTnI assay as 1 ng/L, with concentrations below this limit reported as o1 ng/L. This mechanism may also prove to be
useful for subsequent longitudinal monitoring of the hs-cTnI assay for these important variables (i.e., periodically assessing if precision at
1 ng/L is r33% and LoB r0.6 ng/L).
Moreover, the whole study protocol should be of interest to others wishing to validate and implement hs-cTnI testing across several
different hospitals using either the i2000SR or i1000 analyzers on either the 500-test or 100-test reagent packs. Also, the linearity testing
0%
25%
50%
75%
100%
125%
150%
175%
200%
225%
0 20 40 60 80 100
C
V%
Cardiac Troponin I [ng/L]
hs-cTnI
cTnI
Fig. 3. Precision proﬁle for hs-cTnI and cTnI with patient-pool EDTA plasma samples with concentrations o100 ng/L.
Table 2
Comparability testing on 40 patient-pool EDTA plasma samples for hs-cTnI (ng/L).
Abbott hs-cTnI (n¼8 measures on same samples)
Average hs-cTnI (ng/L) Minimum result Maximum result Absolute difference between
maximum and minimum results
Coefﬁcient variation (CV) (%)
1.6 1.3 2.2 0.8 18
2.3 2.0 2.8 0.8 12
4.1 3.9 4.3 0.4 4
4.7 3.6 5.7 2.1 15
7.1 6.2 8.0 1.8 8
7.9 7.5 8.3 0.7 4
9.7 8.7 10.6 1.9 7
9.7 8.8 10.9 2.1 8
10 9.3 10.6 1.2 5
12 11 21 10 31
13 12 14 2 6
15 13 18 5 12
16 15 17 2 4
17 13 20 7 15
18 16 19 3 5
19 17 20 3 5
20 18 23 5 9
27 24 28 4 5
31 29 33 4 5
37 33 45 12 10
44 40 50 10 7
46 44 50 6 4
53 49 56 7 5
64 62 67 5 3
64 60 70 10 5
117 110 125 15 5
137 131 147 17 4
147 138 156 19 6
167 158 185 27 6
242 207 299 92 15
284 270 300 30 4
419 399 458 59 5
527 489 574 85 6
1145 936 1317 381 12
1349 1250 1412 162 5
1506 1380 1639 259 7
1546 1321 1747 426 11
1641 1534 1853 319 7
3350 3126 3483 357 5
7016 6597 7409 812 4
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was performed by simple serial dilution using the multi-assay diluent. The percent deviation was a little higher than other reports [8,10],
which might be explained using the multi-assay diluent (rather than an undetectable hs-cTnI pool) and the multiple dilutions that were
performed (16 in total). However, considering imprecision estimates into the linearity testing and performing dilutions through the
reference interval and below the reported LoD for the hs-cTnI assay, the practical approach of using the multi-assay diluent may be of
particular importance for laboratories investigating potential interferences, which may be identiﬁed with serial dilutions.
The introduction of a “normal” hs-cTnI patient-pool QC material for validation, implementation and on-going quality assurance is also
unique to this study and for hs-cTn testing. Myocardial injury is being assessed in various acute hospitalized populations [20] with interest
into primary and secondary prevention [21–28], so there is a greater need for the clinical laboratory to monitor this assay below the 99th
percentile. Even for the physicians within emergency departments who want a precise assay at the 99th percentile cutoff, there is also
much interest with some intriguing publications suggesting an undetectable and/or low hs-cTn result may identify patients at low risk for
acute coronary syndrome and possibly early discharge [29–31]. Therefore, monitoring the hs-cTn assays at these decisions points may
become essential [32]. In our educational activities and laboratory reports we always state that cardiac troponin reﬂects myocardial injury
and not necrosis. We also reiterated in activities leading to and after the implementation of the hs-cTnI assay that measurable quantities of
cardiac troponin I will now be more pervasive in patients being evaluated for acute coronary syndrome. The dialog with clinical users
before, during and after the transition to hs-cTnI has been essential to help mitigate confusion around this new assay.
Another aspect not typically addressed for hs-cTn testing (using the same assay) is comparability testing, which is important for
institutions with multiple analyzers or who work in a network and/or laboratory program. For instance, within a city there may be times
when analyzers are down and samples sent to another site for testing or more commonly there will be patients transferred from one
hospital to another for speciﬁc procedures. Therefore, comparability testing for hs-cTnI across hospital core laboratories is essential.
The ﬁndings from this study indicates that agreement, as assessed by CV, is superior for hs-cTnI as compared to cTnI; however there are
still some samples that yield very discrepant results. Speciﬁcally, analytical differences up to 12 ng/L between analyzers testing the same
samples at concentrations below 65 ng/L were observed for the hs-cTnI assay in this study, consistent with another study suggesting up to
10 ng/L as variation [33]. These data lend support that greater absolute changes in hs-cTnI concentrations over time are needed for ruling-
in events [34].
Finally, the implementation was successful, due to the fact that there was already clinical agreement and support for this change, that
there was core laboratory staff available to make the quality control material, to do the analytical testing and the method comparisons
(which in this study showed closer agreement than our previous publication, most likely due to fewer high concentration samples [19]),
and that there was ample education/dissemination activities involving the hs-cTnI change. The good communication and collaboration
within and between laboratory and clinical staff were keys to a successful validation and clinical implementation.
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